Sanofi to acquire mRNA partner Translate Bio for $3.2B

By The Science Advisory Board staff writers

August 4, 2021 -- Sanofi is set to acquire COVID-19 development partner Translate Bio for $3.2 billion, a deal that will bring an mRNA platform, as well as an early stage pipeline in rare pulmonary diseases, into Sanofi's portfolio.

In a statement about the deal, Sanofi said that it plans to accelerate partnered programs that are already under development. The two companies have worked together since mid-2018 to develop mRNA vaccines for COVID-19 and other infectious diseases. Two studies of mRNA vaccines are ongoing: one phase I/II study in COVID-19 and one phase I trial in seasonal influenza. Both studies are set to read out this year.

In addition to developing vaccines for infectious diseases, the companies plan to apply Translate Bio's proprietary mRNA therapeutic platform in other areas, such as immunology, oncology, and rare diseases.

Translate Bio's pipeline has been focused on cystic fibrosis and other rare pulmonary diseases. The company has also been conducting research involving the application of mRNA technology in the development of therapeutic antibodies and vaccines for cancer.

Sanofi will acquire all outstanding shares of Translate Bio common stock for $38 per share in cash, reflecting a total equity value of approximately $3.2 billion. The deal is expected to close in the third quarter.

Sanofi to invest $474M annually on mRNA vaccine R&D
Sanofi will spend approximately 400 million euros ($474 million U.S.) to accelerate the research and development (R&D) of messenger RNA (mRNA)...
Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents.
Sanofi, GSK initiate phase III trial of COVID-19 vaccine
Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine...
New research uncovers how SARS-CoV-2 hijacks RNA host proteins
A new study has uncovered the interactions that SARS-CoV-2 RNA establishes with the host cell proteins, many of which are fundamental for infection. The...
Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country.
Sanofi, Translate Bio begin early-stage trials of mRNA COVID-19 vaccine
Sanofi Pasteur, the vaccine unit of Sanofi, is partnering with Translate Bio on a phase I/II clinical trial for MRT5500, a messenger RNA (mRNA) vaccine...

Copyright © 2021

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter